Bone Biologics

Bone Biologics Doubles Australian Trial Sites for NB1 Spinal Fusion Study, Targets Year-End 2026 Enrollment

- Bone Biologics has expanded its first-in-human pilot trial of NB1 to six Australian hospital sites, doubling the number of participating centers. - The multicenter, randomized study evaluates NB1 in up to 30 adults with degenerative disc disease undergoing transforaminal lumbar interbody fusion. - The company expects to complete patient enrollment by year-end 2026, with fusion success and Oswestry Disability Index change as primary endpoints. - A July 2026 private placement of roughly $3.0 million extends the company's operating runway through Q2 2027 to fund the clinical program.